期刊
LEUKEMIA
卷 17, 期 9, 页码 1738-1752出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.leu.2403099
关键词
FLT3; AML; ITD; receptor tyrosine kinase; tyrosine kinase inhibitor
资金
- NCI NIH HHS [CA91177, CA70970, 1K08CA95600-01A1] Funding Source: Medline
FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据